Toth R, Choi S, Le Naour-Vernet M, Schwanke F, Johnson JL, Tee EE, Yaron-Barir TM, Khochaba E, Derbyshire P, Colo A et al..
2026.
Motif-based substrate mapping of the receptor-like cytoplasmic kinase BIK1 reveals novel components and regulatory nodes of plant immunity.. Nat Plants. 12(2):465-480.
Koprulu M, Smith-Byrne K, Ferolito BRichard, Macdonald-Dunlop E, Luan J'an, Hedman ÅK, Ogamba CFranklin, Kuliesius J, Repetto L, Ramisch A et al..
2026.
Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.. Cell. 189(11):3339-3357.e11.
Kuo H-H, Bhinder B, Gokozan HN, Gorski K, Chandra P, Manohar J, Guevara D, Otilano J, Moyer J, Tranquille M et al..
2026.
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.. Sci Adv. 12(26):eadz3351.
Armstrong AJ, Azad AA, Iguchi T, Stenzl A, Mottet N, Russell D, Rosales M, Haas GP, Saad F, Hussain M et al..
2026.
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.. J Clin Oncol. :JCO2402829.
Nazzaro M, Mardis ER, Canella A, Bhinder B, Elemento O, Behbehani G, Currier M, Glaspell A, Lee DA, Cripe TP et al..
2026.
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.. Mol Ther Oncol. 34(1):201147.
Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH et al..
2026.
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.. J Clin Oncol. :JCO2502834.
Podaza E, Capuano J, Kuo H-H, Assaad MAl, Markowitz G, M Revuelta V, Nguyen J, Irizarry A, Ravichandran H, Ackermann S et al..
2026.
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC.. Cell Rep Methods. :101339.